iBio, Inc. (IBIO)
Key Executives
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. Martin B. Brenner D.V.M., Ph.D. | CEO & Chief Scientific Officer | 577.31k | -- | 1971 |
Mr. Felipe Duran | Chief Financial Officer | 1.07M | -- | 1980 |
Stephen Kilmer | Investor Relations Officer | -- | -- | -- |
Mr. Marc Banjak J.D. | General Counsel | -- | -- | -- |
Mr. Robert B. Kay | Interim Secretary & Interim Treasurer | 92.69k | -- | 1940 |
iBio, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 26
Description
iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.
Corporate Governance
Recent Events
- Apr 16, 2024S-3: Offering RegistrationsSee Full Filing
- Apr 04, 2024D: Additional FormsSee Full Filing
- Apr 01, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Feb 26, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Feb 21, 20248-K: Corporate Changes & Voting MattersSee Full Filing